Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties

References

• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8:140 - 74; http://dx.doi.org/10.1159/000082102; PMID: 15564720
   PubMedGoogle Scholar
• Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125:1678 - 85; PMID: 6157744
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823 - 37; http://dx.doi.org/10.1016/j.molimm.2007.06.151; PMID: 17768100
   PubMed Web of Science ®Google Scholar
• Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phosphoproteins and calmodulin-binding proteins. J Biol Chem 2008; 283:18545 - 52; http://dx.doi.org/10.1074/jbc.M800784200; PMID: 18474602
   PubMed Web of Science ®Google Scholar
• Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010; 70:1445 - 76; http://dx.doi.org/10.2165/11201110-000000000-00000; PMID: 20614951
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417 - 23; http://dx.doi.org/10.1182/blood-2004-08-3175; PMID: 15494430
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, et al, German Low-Grade Lymphoma Study Group. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104:3064 - 71; http://dx.doi.org/10.1182/blood-2004-04-1323; PMID: 15284112
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725 - 32; http://dx.doi.org/10.1182/blood-2005-01-0016; PMID: 16123223
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108:3295 - 301; http://dx.doi.org/10.1182/blood-2006-05-021113; PMID: 16873669
   PubMed Web of Science ®Google Scholar
• Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004; 104:584
   Web of Science ®Google Scholar
• Fowler NH. Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. P.T. 2011; 36:590 - 8
   PubMedGoogle Scholar
• Salles G, Seymour JF, Offner F, López-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377:42 - 51; http://dx.doi.org/10.1016/S0140-6736(10)62175-7; PMID: 21176949
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853 - 8; http://dx.doi.org/10.1200/JCO.2009.26.5827; PMID: 20439641
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H, et al, German Low Grade Lymphoma Study Group (GLSG). Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108:4003 - 8; http://dx.doi.org/10.1182/blood-2006-04-016725; PMID: 16946304
   PubMed Web of Science ®Google Scholar
• Martinelli G, Schmitz SF, Utiger U, Cerny T, Hess U, Bassi S, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480 - 4; http://dx.doi.org/10.1200/JCO.2010.28.4786; PMID: 20697092
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev 2009; CD006552; PMID: 19370640
   PubMedGoogle Scholar
• Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, ESMO Guidelines Working Group. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22:Suppl 6 vi50 - 4; http://dx.doi.org/10.1093/annonc/mdr377; PMID: 21908504
   PubMed Web of Science ®Google Scholar
• Tilly H, Dreyling M, ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21:Suppl 5 v172 - 4; http://dx.doi.org/10.1093/annonc/mdq203; PMID: 20555073
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22:Suppl 6 vi59 - 63; http://dx.doi.org/10.1093/annonc/mdr388; PMID: 21908506
   PubMed Web of Science ®Google Scholar
• Lemery SJ, Zhang JZ, Rothmann MD, Yang J, Earp JC, Zhao H, et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res 2010; 16:4331 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-10-0570; PMID: 20601446
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al, Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28:1749 - 55; http://dx.doi.org/10.1200/JCO.2009.25.3187; PMID: 20194866
   PubMed Web of Science ®Google Scholar
• Illidge T, Morschhauser F. Radioimmunotherapy in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24:279 - 93; http://dx.doi.org/10.1016/j.beha.2011.03.005; PMID: 21658624
   PubMed Web of Science ®Google Scholar
• Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica 2010; 95:135 - 43; http://dx.doi.org/10.3324/haematol.2008.001628; PMID: 19773256
   PubMed Web of Science ®Google Scholar
• Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003; 63:5480 - 9; PMID: 14500384
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004; 103:2738 - 43; http://dx.doi.org/10.1182/blood-2003-06-2031; PMID: 14551143
   PubMed Web of Science ®Google Scholar
• Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101:1045 - 52; http://dx.doi.org/10.1182/blood-2002-06-1761; PMID: 12393541
   PubMed Web of Science ®Google Scholar
• Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 402; http://dx.doi.org/10.1182/blood-2009-06-225979; PMID: 20194898
   PubMed Web of Science ®Google Scholar
• Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117:4519 - 29; http://dx.doi.org/10.1182/blood-2010-07-296913; PMID: 21378274
   PubMed Web of Science ®Google Scholar
• Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118:358 - 67; http://dx.doi.org/10.1182/blood-2010-09-305847; PMID: 21444918
   PubMed Web of Science ®Google Scholar
• MabThera SmPC. June 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Accessed October 2012.
   Google Scholar
• Clinical trials information is available at: http://www.clinicaltrials.gov. Accessed October 2012.
   Google Scholar
• Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem 1998; 273:344 - 8; http://dx.doi.org/10.1074/jbc.273.1.344; PMID: 9417086
   PubMed Web of Science ®Google Scholar
• Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99:3256 - 62; http://dx.doi.org/10.1182/blood.V99.9.3256; PMID: 11964291
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170 - 7; http://dx.doi.org/10.1182/blood-2008-04-149161; PMID: 18583569
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004; 104:1793 - 800; http://dx.doi.org/10.1182/blood-2004-01-0039; PMID: 15172969
   PubMed Web of Science ®Google Scholar
• Cragg MS. CD20 antibodies: doing the time warp. Blood 2011; 118:219 - 20; http://dx.doi.org/10.1182/blood-2011-04-346700; PMID: 21757627
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119:2143 - 59; PMID: 19620786
   PubMed Web of Science ®Google Scholar
• Jak M, van Bochove G, Klein C, Umana P, Eldering E, Van Oers MHJ. CD40 stimulation sensitizes CLL cells to CD20-triggered cell death by rituximab and GA101 via a different mechanism. Blood 2011; 118:5178 - 88
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119:3523 - 33; http://dx.doi.org/10.1182/blood-2011-12-395541; PMID: 22354003
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99:754 - 8; http://dx.doi.org/10.1182/blood.V99.3.754; PMID: 11806974
   PubMed Web of Science ®Google Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635 - 42; http://dx.doi.org/10.1182/blood-2004-03-1110; PMID: 15226177
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109 - 14; PMID: 9242542
   PubMed Web of Science ®Google Scholar
• Ferrara C, Stuart F, Sondermann P, Brünker P, Umaña P. The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. J Biol Chem 2006; 281:5032 - 6; http://dx.doi.org/10.1074/jbc.M510171200; PMID: 16330541
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108:2648 - 54; http://dx.doi.org/10.1182/blood-2006-04-020057; PMID: 16825493
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21:3940 - 7; http://dx.doi.org/10.1200/JCO.2003.05.013; PMID: 12975461
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115:5191 - 201; http://dx.doi.org/10.1182/blood-2010-01-263533; PMID: 20223920
   PubMed Web of Science ®Google Scholar
• Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HT, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118:2530 - 40; http://dx.doi.org/10.1182/blood-2011-01-330357; PMID: 21768293
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177:362 - 71; PMID: 16785532
   PubMed Web of Science ®Google Scholar
• Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood 2006; 108:1975 - 8; http://dx.doi.org/10.1182/blood-2006-04-014639; PMID: 16705086
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J Biol Chem 2007; 282:15073 - 80; http://dx.doi.org/10.1074/jbc.M701654200; PMID: 17395584
   PubMed Web of Science ®Google Scholar
• Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol 2008; 45:2861 - 8; http://dx.doi.org/10.1016/j.molimm.2008.01.034; PMID: 18346788
   PubMed Web of Science ®Google Scholar
• Du J, Yang H, Guo Y, Ding J. Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol 2009; 46:2419 - 23; http://dx.doi.org/10.1016/j.molimm.2009.04.009; PMID: 19427037
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 2006; 107:1070 - 7; http://dx.doi.org/10.1182/blood-2005-04-1769; PMID: 16223774
   PubMed Web of Science ®Google Scholar
• Perosa F, Favoino E, Vicenti C, Guarnera A, Racanelli V, De Pinto V, et al. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. J Immunol 2009; 182:416 - 23; PMID: 19109173
   PubMed Web of Science ®Google Scholar
• Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, Vandlen RL. Isolation and characterization of the B-cell marker CD20. Biochemistry 2005; 44:15150 - 8; http://dx.doi.org/10.1021/bi0511078; PMID: 16285718
   PubMed Web of Science ®Google Scholar
• Li B, Zhao L, Guo H, Wang C, Zhang X, Wu L, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009; 114:5007 - 15; http://dx.doi.org/10.1182/blood-2009-06-225474; PMID: 19828699
   PubMed Web of Science ®Google Scholar
• Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009; 94:423 - 7; http://dx.doi.org/10.3324/haematol.2008.001024; PMID: 19211644
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon MO, Coleman M, et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J Clin Oncol 2009; 27:3346 - 53; http://dx.doi.org/10.1200/JCO.2008.19.9117; PMID: 19451441
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Hernandez-Ilizaliturri FJ, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113:1062 - 70; http://dx.doi.org/10.1182/blood-2008-07-168146; PMID: 18941114
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18:1395 - 403; http://dx.doi.org/10.1158/1078-0432.CCR-11-0850; PMID: 22223529
   PubMed Web of Science ®Google Scholar
• Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103:4429 - 31; http://dx.doi.org/10.1182/blood-2003-11-3883; PMID: 15016644
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17:3793 - 803; PMID: 10577851
   PubMed Web of Science ®Google Scholar
• Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20:2453 - 63; http://dx.doi.org/10.1200/JCO.2002.11.076; PMID: 12011122
   PubMed Web of Science ®Google Scholar
• Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99:4336 - 42; http://dx.doi.org/10.1182/blood.V99.12.4336; PMID: 12036859
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156 - 64; http://dx.doi.org/10.1200/JCO.2008.17.2015; PMID: 18854568
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Markus TM, Shipley D, Thompson D, Rotman R, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 2009; 9:223 - 8; http://dx.doi.org/10.3816/CLM.2009.n.044; PMID: 19525191
   PubMedGoogle Scholar
• Morschhauser F, Marlton P, Vitolo U, Lindén O, Seymour JF, Crump M, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21:1870 - 6; http://dx.doi.org/10.1093/annonc/mdq027; PMID: 20157180
   PubMed Web of Science ®Google Scholar
• Sikder MA, Friedberg JW. Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep 2008; 3:187 - 93; http://dx.doi.org/10.1007/s11899-008-0027-5; PMID: 20425465
   PubMedGoogle Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591 - 604; http://dx.doi.org/10.1074/jbc.M009483200; PMID: 11096108
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Vose JM, Kahl BS, Brunvand MW, Goy A, Kasamon YL, et al. A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. Blood 2009; 114:3742
   PubMed Web of Science ®Google Scholar
• Hayden-Ledbetter MS, Cerveny CG, Espling E, Brady WA, Grosmaire LS, Tan P, et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin Cancer Res 2009; 15:2739 - 46; http://dx.doi.org/10.1158/1078-0432.CCR-08-1694; PMID: 19351771
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al, 405 Study Investigators. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012; 119:3698 - 704; http://dx.doi.org/10.1182/blood-2011-09-378323; PMID: 22389254
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, et al, 409 Study Investigators. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol 2012; 157:438 - 45; http://dx.doi.org/10.1111/j.1365-2141.2012.09086.x; PMID: 22409295
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Plesner T, Johnson P, Pedersen L, Walewski J, Hellman A, et al. HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma. Blood 2005; 106:Abstract 4760; PMID: 16174759
   PubMedGoogle Scholar
• Uchiyama S, Suzuki Y, Otake K, Yokoyama M, Ohta M, Aikawa S, et al. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope. Cancer Sci 2010; 101:201 - 9; http://dx.doi.org/10.1111/j.1349-7006.2009.01392.x; PMID: 19930155
   PubMed Web of Science ®Google Scholar
• Engelberts P, Beurskens F, Mackus W, Bakker J, Vink T, Tiebout A, et al. Ofatumuab targets a conformational membrane-proximal epitope which contains amino acids located in the small and large loops of CD20. Haematologica 2010; 95:46
   Web of Science ®Google Scholar
• Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008; 181:822 - 32; PMID: 18566448
   PubMed Web of Science ®Google Scholar
• Herter S, Waldhauer I, Otz T, Herting F, Lang S, Nicolini V, et al. . Superior Efficacy of the Novel Type II, Glycoengineered CD20 Antibody GA101vs. the Type I CD20 Antibodies Rituximab and Ofatumumab. Blood2010; 116:3925.
   Google Scholar
• Wu L, Wang C, Zhang D, Zhang X, Qian W, Zhao L, et al. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Lett 2010; 292:208 - 14; http://dx.doi.org/10.1016/j.canlet.2009.12.004; PMID: 20056316
   PubMed Web of Science ®Google Scholar
• Baritaki S, Militello L, Malaponte G, Spandidos DA, Salcedo M, Bonavida B. The anti-CD20 mAb LFB-R603 interrupts the dysregulated NF-κB/Snail/RKIP/PTEN resistance loop in B-NHL cells: role in sensitization to TRAIL apoptosis. Int J Oncol 2011; 38:1683 - 94; PMID: 21455568
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 2001; 19:3918 - 28; PMID: 11579112
   PubMed Web of Science ®Google Scholar
• Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10:7792 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-04-0756; PMID: 15585610
   PubMed Web of Science ®Google Scholar
• Nishida M, Usuda S, Okabe M, Miyakoda H, Komatsu M, Hanaoka H, et al. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 2007; 31:29 - 40; PMID: 17549402
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin’s lymphoma. Clin Cancer Res 2004; 10:2868 - 78; http://dx.doi.org/10.1158/1078-0432.CCR-03-0493; PMID: 15102696
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012; 18:1395 - 403; http://dx.doi.org/10.1158/1078-0432.CCR-11-0850; PMID: 22223529
   PubMed Web of Science ®Google Scholar